Proleukin

(Aldesleukin)

Phase 3Protein / enzyme

Aldesleukin is used to treat advanced kidney cancer and melanoma (a type of skin cancer) by helping the immune system fight cancer cells.[1] Proleukin is currently being investigated across 24 indications[3], with its most advanced program in Phase 3.[1]

Proleukin is one of 541 small molecule programs targeting Ovarian Cancer. It is currently in Phase 3.

Indications

322

Total Trials

Active Trials

540

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Ovarian CancerNot yet recruiting

Hepatitis CActive, not recruiting

TumorsRecruiting

Clinical Stage IV Gastric Cancer AJCC V8Active, not recruiting

Solid TumorRecruiting

Clear Cell Renal Cell CarcinomaActive, not recruiting

Advanced Non-Small Cell Lung CancerRecruiting

Metastatic Solid CancersActive, not recruiting

NeuroblastomaCompleted

MelanomaCompleted

Ovarian CancerPhase 2

Not yet recruiting

Hepatitis CPreclinical

Active, not recruiting

TumorsPhase 2

Recruiting

Clinical Stage IV Gastric Cancer AJCC V8Phase 1

Active, not recruiting

Solid TumorPreclinical

Recruiting

Clear Cell Renal Cell CarcinomaPreclinical

Active, not recruiting

Advanced Non-Small Cell Lung CancerPhase 2

Recruiting

Metastatic Solid CancersPhase 1

Active, not recruiting

NeuroblastomaPhase 3

Completed

MelanomaPhase 3

Completed

Showing 10 of 24 indications

Competition

Competitive Landscape

449 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Proleukin

IIovance Biotherapeutics, Inc.

Phase 3

4 2

Neoadjuvant Therapy

SSun Yat-sen University

Phase 3

2 3

Nanocrystalline Megestrol Acetate

Changchun GeneScience Pharmaceutical Co., Ltd.

Phase 3

1 4

Consolidative Therapy

SSun Yat-sen University

Phase 3

2 5

Remeron

OOrganon and Co

Preclinical

1 6

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—7

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—8

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

—9

Valemetostat Tosylate

Daiichi Sankyo

Preclinical

1 10

Treatment

GSK

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Active, not recruiting

Soft Tissue Sarcoma

NCT03449108

Q3 2027

Phase 1/2Recruiting

Cancer

NCT07063875

Q4 2027

Phase 2Active, not recruiting

Advanced Malignancies

NCT01697527

Phase 1/2Recruiting

Metastatic Cancer

NCT05296564

Q1 2028

Phase 1Recruiting

Non-Small Cell Lung Cancer

NCT05493566

Clinical

Trials by Indication[1]

Metastatic Melanoma32 trials

Vaccine Therapy With High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma

Completed·UUniversity of Illinois at Chicago·Phase 2·NCT00003568

Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Metastatic Melanoma

Terminated·FFred Hutchinson Cancer Center·Phase 1·NCT01106235·12 enrolled

Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT01160445·9 enrolled

Show 29 more trials

Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Anti-gp100:154-162 TCR Gene Engineered Lymphocytes

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT00509496·21 enrolled

Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic Melanoma

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT02500576·18 enrolled

Vaccine Therapy in Treating Patients With Metastatic Melanoma Who Are Undergoing Surgery for Lymph Node and Tumor Removal

Completed·—·Phase 1/2·NCT00003229

Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma

Completed·FFred Hutchinson Cancer Center·Phase 1/2·NCT00871481·10 enrolled

Immunization With gp100 Protein Vaccine in Treating Patients With Metastatic Melanoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00072085

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00019721

Gene Therapy in Treating Patients With Metastatic Melanoma

Completed·UUniversity of Colorado, Denver·Phase 1·NCT00005943

Vaccine Therapy in Treating Patients With Metastatic Melanoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00019994

Phase II Study of Short-Term Cultured Anti-Tumor Autologous Lymphocytes After Lymphocyte-Depleting Chemotherapy in Metastatic Melanoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00513604·158 enrolled

Biological Therapy in Treating Patients With Metastatic Melanoma

Completed·FFred Hutchinson Cancer Center·Phase 1/2·NCT00002786·20 enrolled

Vaccine Therapy in Treating Patients With Refractory Metastatic Melanoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00020397

Gene-Modified White Blood Cells Followed By Interleukin-2 and Vaccine Therapy in Treating Patients With Metastatic Melanoma

Completed·NNational Institutes of Health Clinical Center (CC)·Phase 1·NCT00085462·61 enrolled

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma That Has Not Responded to Previous Treatment

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00022438

Mechanism of Action of High-Dose IL-2 (Aldesleukin) in Metastatic Melanoma and Kidney Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00304460·138 enrolled

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01993719·33 enrolled

Vaccine Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00054535

Vaccine Therapy With or Without Interleukin-2 After Chemotherapy and an Autologous White Blood Cell Infusion in Treating Patients With Metastatic Melanoma

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT00303836·58 enrolled

CD8+ Antigen-Specific T Cells, Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Melanoma

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT02027935·16 enrolled

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Recurrent Metastatic Melanoma

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00019175

Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT01740557·10 enrolled

Chemotherapy Followed by Infusion of DMF5 Cells to Treat Metastatic Melanoma

Terminated·NNational Cancer Institute (NCI)·Phase 1/2·NCT00924001·1 enrolled

Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT00019682·185 enrolled

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00019669

Vaccine Therapy Following Therapeutic Autologous Lymphocytes and Cyclophosphamide in Treating Patients With Metastatic Melanoma

Completed·FFred Hutchinson Cancer Center·Phase 1·NCT01339663·12 enrolled

Vaccine Therapy in Treating Patients With Recurrent or Refractory Metastatic Melanoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00019383

Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic Melanoma

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT01807182·11 enrolled

Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI...

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01319565·102 enrolled

Modified Tumor Infiltrating Lymphocytes for Metastatic Melanoma

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT01369875·2 enrolled

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT00019214

Melanoma16 trials

Anti-MART-1 F5 Cells Plus ALVAC MART-1 Vaccine to Treat Advanced Melanoma

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT00612222·4 enrolled

Anti-gp100 Cells Plus ALVAC gp100 Vaccine to Treat Advanced Melanoma

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT00610311·3 enrolled

Anti-MART-1 F5 Lymphocytes to Treat High-Risk Melanoma Patients

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT00706992·50 enrolled

Show 13 more trials

Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma

Terminated·RRutgers, The State University of New Jersey·Phase 2·NCT02748564·10 enrolled

Vaccine Plus Interleukin-2 in Treating Patients With Advanced Melanoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00005949·50 enrolled

Chemotherapy Followed by gp100 Lymphocytes and Aldesleukin to Treat Melanoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00665470·10 enrolled

Combined BRAF-Targeted Therapy & Immunotherapy for Melanoma

Terminated·MMassachusetts General Hospital·Phase 2·NCT01754376·6 enrolled

Vaccine Therapy in Treating Patients With Melanoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00020358

Indomethacin Plus Biological Therapy in Treating Patients With Advanced Melanoma

Completed·SSt. Luke's Medical Center·Phase 2·NCT00002535

Vemurafenib and White Blood Cell Therapy for Advanced Melanoma

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT01585415·12 enrolled

Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage III or Stage IV Melanoma

Terminated·UUniversity of Southern California·Phase 2·NCT00006113·25 enrolled

Chemotherapy Followed by Biological Therapy in Treating Patients With Stage IV Melanoma That Cannot be Treated With Surgery

Completed·—·Phase 2·NCT00014092

Laboratory-Treated T Cells and Aldesleukin After Cyclophosphamide in Treating Patients With Stage IV Melanoma

Completed·FFred Hutchinson Cancer Center·Phase 1/2·NCT00553306·10 enrolled

High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery

Terminated·CCINJRegulatory·Phase 2·NCT02203604·9 enrolled

Interferon Alfa With or Without Combination Chemotherapy Plus Interleukin-2 in Treating Patients With Melanoma

Completed·MM.D. Anderson Cancer Center·Phase 3·NCT00002882·140 enrolled

Aldesleukin With or Without Vaccine Therapy in Treating Patients With Stage IV Melanoma

Completed·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00726739·21 enrolled

Kidney Cancer11 trials

Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00126490·19 enrolled

Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer

Terminated·UUniversity of Washington·Phase 1·NCT03260504·6 enrolled

Interleukin-2 and Bryostatin 1 in Treating Patients With Advanced Kidney Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00032188·65 enrolled

Show 8 more trials

Interleukin-2 in Treating Patients With Metastatic or Recurrent Kidney Cancer

Unknown status·—·Phase 2·NCT00002846·14 enrolled

Medroxyprogesterone or Interferon and/or Aldesleukin in Treating Patients With Metastatic Kidney Cancer

Completed·CCentre Leon Berard·Phase 3·NCT00416429·456 enrolled

Combination Chemotherapy and Biological Therapy In Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed Surgically

Unknown status·CCancer Biotherapy Research Group·Phase 2·NCT00003664·30 enrolled

Interleukin-2 and Interferon in Treating Patients With Metastatic Kidney Cancer

Completed·CCentre Leon Berard·Phase 3·NCT00416871·220 enrolled

Interleukin-2 in Treating Patients With Metastatic Kidney Cancer

Completed·—·Phase 4·NCT00006864

High-Dose Interferon Alfa and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer or Melanoma

Completed·HHoag Memorial Hospital Presbyterian·Phase 2·NCT00003091·40 enrolled

Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer

Unknown status·JJonsson Comprehensive Cancer Center·Phase 2·NCT00301990·65 enrolled

Interleukin-2, Interferon Alfa, and Fluorouracil Compared With Observation in Treating Patients Who Have Undergone Surgery for Kidney Cancer

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00053807·96 enrolled

Metastatic Cancer9 trials

Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT00670748·45 enrolled

CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 1/2·NCT01583686·15 enrolled

T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT02111850·21 enrolled

Show 6 more trials

MAGE-A3/12 Metastatic Cancer Treatment With Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes

Terminated·NNational Cancer Institute (NCI)·Phase 1/2·NCT01273181·9 enrolled

Interleukin-2 Plus Interferon Alfa in Treating Adults With Metastatic Cancer

Completed·HHoag Memorial Hospital Presbyterian·Phase 2·NCT00002504

Vaccine Therapy in Treating Patients With Metastatic Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00021164

Phase II Study of Metastatic Cancer That Overexpresses P53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-P53 TCR-Gene Engineered Lymphocytes

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00393029·12 enrolled

Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers

Recruiting·HHadassah Medical Organization·Phase 1/2·NCT05296564·3 enrolled

Gene-Modified Lymphocytes, High-Dose Aldesleukin, and Vaccine Therapy in Treating Patients With Progressive or Recurrent Metastatic Cancer

Terminated·NNational Institutes of Health Clinical Center (CC)·Phase 2·NCT00704938·3 enrolled

Breast Cancer8 trials

Biological Therapy in Treating Women With Stage IV Breast Cancer

Completed·BBarbara Ann Karmanos Cancer Institute·Phase 1·NCT00027807·6 enrolled

A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer

Suspended·UUniversity of Southern California·Phase 1·NCT05989828·20 enrolled

Biological Therapies Following Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, or Advanced Breast Cancer

Terminated·MMasonic Cancer Center, University of Minnesota·Phase 1·NCT00005993

Show 5 more trials

Cellular Adoptive Immunotherapy in Treating a Patient Who Has Undergone a Donor Stem Cell Transplant for Breast Cancer That Has Spread to the Lung

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00301730·1 enrolled

Biological Therapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Breast Cancer

Unknown status·UUniversity of Illinois at Chicago·Phase 1·NCT00002616·36 enrolled

Biological Therapy in Treating Women With Metastatic Breast Cancer

Unknown status·SSt. Luke's Medical Center·Phase 1/2·NCT00002780·60 enrolled

Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00003199·50 enrolled

Combination Chemotherapy Plus Biological Therapy in Treating Patients With Stage II or Stage III Breast Cancer

Withdrawn·RRoger Williams Medical Center·Phase 1/2·NCT00022230

75 more indications

Lymphoma8 trials

Rituximab and Interleukin-2 in Treating Patients With Relapsed or Refractory Intermediate- or High-Grade Non-Hodgkin's Lymphoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00059904

Bryostatin 1 and Interleukin-2 in Treating Patients With Refractory Solid Tumors or Lymphoma

Completed·NNational Institute on Aging (NIA)·Phase 1·NCT00003993·24 enrolled

Combination Chemotherapy, Peripheral Stem Cell Transplantation, and Biological Therapy in Treating Patients With Solid Tumors or Lymphoma

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00027937

Show 5 more trials

Cellular Adoptive Immunotherapy in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma

Completed·—·Phase 1·NCT00182650·5 enrolled

CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT00924326·43 enrolled

Allogeneic Epstein Barr Virus-Specific Cytotoxic T-Lymphocytes in Treating Patients With Progressive, Relapsed, or Refractory Hodgkin's Lymphoma

Unknown status·MMilton S. Hershey Medical Center·Phase 1·NCT00006100

Immunotherapy Using Cyclosporine, Interferon Gamma, and Interleukin-2 After High-Dose Myeloablative Chemotherapy With Autologous Stem Cell Transplantation in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma

Completed·CChildren's Oncology Group·Phase 2/3·NCT00070187·24 enrolled

Interleukin-2 or Observation Following Radiation Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT00002649·206 enrolled

Neuroblastoma7 trials

Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT00026312·1,449 enrolled

Interleukin-2 in Treating Children With Stage IV Neuroblastoma Who Have Received Induction Therapy and Peripheral Stem Cell Transplantation

Unknown status·SSt. Anna Kinderkrebsforschung·Phase 2·NCT00003743·25 enrolled

High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)

Recruiting·SSt. Anna Kinderkrebsforschung·Phase 3·NCT01704716·3,300 enrolled

Show 4 more trials

Pilot Study of Zoledronic Acid and Interleukin-2 for Refractory Pediatric Neuroblastoma

Terminated·UUniversity of Alabama at Birmingham·Phase 1·NCT01404702·4 enrolled

Monoclonal Antibody Therapy With Sargramostim and Interleukin-2 in Treating Children With Neuroblastoma

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00005576·6 enrolled

ch14.18 Pharmacokinetic Study in High-risk Neuroblastoma

Completed· United Therapeutics logo

United Therapeutics·Phase 1/2·NCT01592045·28 enrolled

Biological Therapy and Gene Therapy in Treating Children With Recurrent or Refractory Neuroblastoma

Completed·FFred Hutchinson Cancer Center·Phase 1·NCT00006480

Interleukin6 trials

A Study of Zidovudine Plus Interleukin-2 in HIV-Infected Patients Who Have No Symptoms of Infection But Who Have Tender Lymph Nodes

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00001005·30 enrolled

Interleukin-2 and Stem Cell Factor in Treating Patients With AIDS or AIDS-Related Cancer

Completed·RRoswell Park Cancer Institute·Phase 1·NCT00058045·1 enrolled

A Phase I Study of Autologous, Activated CD8(+) Lymphocytes Expanded In Vitro and Infused With or Without Recombinant Interleukin-2 to Patients With AIDS or Severe ARC

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000680·6 enrolled

Show 3 more trials

Subcutaneously Administered Aldesleukin ( Interleukin-2; IL-2 ) Therapy in HIV-Infected Patients

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000821·78 enrolled

Vaccine Therapy, Interleukin-2, and Sargramostim in Treating Patients With Advanced Tumors

Completed·GGeorgetown University·Phase 2·NCT00003125·24 enrolled

Effects of Giving Interleukin-2 (IL-2) Plus Anti-HIV Therapy to HIV-Positive Patients With CD4 Cell Counts of at Least 350 Cells/mm3

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000948·72 enrolled

Acute Myeloid Leukemia6 trials

Interleukin-2 Plus Histamine Dihydrochloride in Treating Patients With Acute Myeloid Leukemia

Completed·MMaxim Pharmaceuticals·Phase 3·NCT00003991·360 enrolled

Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT00006363·720 enrolled

High Dose Chemotherapy, Peripheral Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Acute Myeloid Leukemia

Completed·RRoswell Park Cancer Institute·Phase 3·NCT00002945·61 enrolled

Show 3 more trials

Combination Chemotherapy, Interleukin-2, and Peripheral Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia

Unknown status·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00004128·2,000 enrolled

Donor Peripheral Stem Cell Transplant in Treating Patients With Relapsed Acute Myeloid Leukemia

Completed·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00274846·21 enrolled

Decitabine, Donor Natural Killer Cells, and Aldesleukin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Completed·SSumithira Vasu·Phase 1·NCT02316964·8 enrolled

Multiple Myeloma4 trials

Vaccine Therapy in Treating Patients With Multiple Myeloma Who Have Undergone Stem Cell Transplantation

Completed·FFred Hutchinson Cancer Research Center/University of Washington Cancer Consortium·Phase 1·NCT00002787·22 enrolled

TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma

Withdrawn·JJonsson Comprehensive Cancer Center·Phase 1·NCT03506802

Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon Alfa in Treating Patients With Advanced Multiple Myeloma

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00006244·36 enrolled

Show 1 more trial

Interferon-gamma or Aldesleukin and Vaccine Therapy in Treating Patients With Multiple Myeloma

Completed·MMayo Clinic·Phase 2·NCT00616720·15 enrolled

Ovarian Cancer3 trials

Allogeneic Natural Killer Cells in Patients With Recurrent Ovarian Cancer, Fallopian Tube, and Primary Peritoneal Cancer

Terminated·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00652899·14 enrolled

T-Cell Infusion, Aldesleukin, and Utomilumab in Treating Patients With Recurrent Ovarian Cancer

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT03318900·5 enrolled

A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies.

Not yet recruiting·UUniversity of Chicago·Phase 1/2·NCT07389239·24 enrolled

Non-Small Cell Lung Cancer3 trials

Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer

Recruiting·EEmory University·Phase 1·NCT05493566·15 enrolled

Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and GM-CSF in Treating Patients With Recurrent, Refractory, or Metastatic Non-Small Cell Lung Cancer

Terminated·RRoger Williams Medical Center·Phase 1·NCT00569296·5 enrolled

Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma

Terminated·FFred Hutchinson Cancer Center·Phase 1/2·NCT02408016·11 enrolled

Immunotherapy3 trials

T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT02280811·12 enrolled

T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01967823·11 enrolled

Low Dose IL2 Immunotherapy in AD

Completed·TThe Methodist Hospital Research Institute·Phase 1·NCT05821153·8 enrolled

Bone Marrow Transplantation3 trials

Interleukin-2 in Treating Children Who Have Undergone Bone Marrow Transplantation for Acute Myeloid Leukemia

Completed·CChildren's Oncology Group·Phase 1·NCT00009698·1 enrolled

Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT00002798·880 enrolled

Interleukin-2 Following Bone Marrow Transplantation in Treating Patients With Hematologic Cancer

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT00003962

Type 1 Diabetes3 trials

Adaptive Study of IL-2 Dose Frequency on Regulatory T Cells in Type 1 Diabetes

Completed·—·Phase 1/2·NCT02265809·41 enrolled

Dose-effect Relationship of Low-dose IL-2 in Type 1 Diabetes

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 1/2·NCT01353833·25 enrolled

Regulatory T Cells in Type 1 Diabetes Patients Treated With IL-2

Completed·—·Phase 1/2·NCT01827735·40 enrolled

Mycosis Fungoides2 trials

Interleukin-2 in Treating Patients With Mycosis Fungoides or Sezary Syndrome

Terminated·NNorthwestern University·Phase 2·NCT00005788

Interleukin-12 and Interleukin-2 in Treating Patients With Mycosis Fungoides

Terminated·NNational Cancer Institute (NCI)·Phase 1/2·NCT00052377·46 enrolled

Papilloma2 trials

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01585428·29 enrolled

E7 TCR T Cells for Human Papillomavirus-Associated Cancers

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT02858310·224 enrolled

Effectiveness2 trials

Safety and Effectiveness of L2-7001 (Interleukin-2) in HIV-Positive Patients Receiving Anti-HIV Therapy

Unknown status·CChiron Corporation·Phase 1·NCT00002449·212 enrolled

The Safety and Effectiveness of Interleukin-2 Plus Zidovudine in Patients With AIDS or AIDS Related Complex

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000986·18 enrolled

Hematologic Cancer2 trials

Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00010192·30 enrolled

Combination Chemotherapy Plus Infusion of White Blood Cells in Treating Patients With Hematologic Cancer

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT00003243

HIV2 trials

A Study to Evaluate the Effects of Giving IL-2 Alone to HIV-Positive Patients With CD4 Cell Counts of at Least 350 Cells/mm3 Who Do Not Wish to Receive Anti-HIV Therapy

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000909·36 enrolled

A Study to Evaluate the Effects of Giving Proleukin (rIL-2) to HIV-Positive Patients With CD4 Counts Greater Than 300 Cells/mm3

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00000949·460 enrolled

Biological Therapy2 trials

Vaccine Therapy and Biological Therapy in Treating Patients With Advanced Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00019084

Biological Therapy in Treating Patients With Metastatic Cancer

Completed·HHoag Memorial Hospital Presbyterian·Phase 2·NCT00002733·30 enrolled

Natural Killer Cell2 trials

CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploid Donor Natural Killer Cell Treatment in Older AML in First Complete Remission

Withdrawn·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT01639456

Donor Umbilical Cord Blood Natural Killer Cells, Aldesleukin and Umbilical Cord Blood Transplant in Patients With Refractory Hematologic Cancers.

Terminated·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00354172·16 enrolled

Drug Therapy2 trials

Treatment With Interleukin-2 (IL-2) Plus Combination Anti-HIV-Drug Therapy (HAART) for Patients Formerly in ACTG 328

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00000923·110 enrolled

Interleukin-2 (IL-2) Treatment for HIV Infected Patients Who Have Interrupted Their Anti-HIV Drug Therapy

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00038259·21 enrolled

Stem Cell Transplant2 trials

Donor Natural Killer Cells and Aldesleukin in Treating Patients w/High Risk AML Undergoing Donor Stem Cell Transplant

Completed·MMasonic Cancer Center, University of Minnesota·Phase 1/2·NCT00303667·50 enrolled

Donor White Blood Cell Infusions and Interleukin-2 in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed Advanced Lymphoid Cancer

Completed·FFred Hutchinson Cancer Center·Phase 1/2·NCT00248430·20 enrolled

Prostate Cancer2 trials

Vaccine Therapy Plus Sargramostim and Interleukin-2 Compared With Nilutamide Alone in Treating Patients With Prostate Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00020254

Biological Therapy in Treating Patients With Prostate Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT00002637·25 enrolled

Cancer2 trials

Treated Blood Cells, Cyclophosphamide, Fludarabine Phosphate, and Aldesleukin in Treating Patients With Cancer

Terminated·CCancer Research UK·Phase 1·NCT01212887·14 enrolled

Adding IL-2 to Tebentafusp to Eradicate Cancer Progression

Recruiting·SSt Vincent's Hospital, Sydney·Phase 1/2·NCT07063875·8 enrolled

Mantle Cell Lymphoma2 trials

Combination Chemotherapy, Bone Marrow or Peripheral Stem Cell Transplantation, and/or Biological Therapy in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma

Completed·NNorthwestern University·Phase 2·NCT00004231

Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphoma

Completed·FFred Hutchinson Cancer Center·Phase 1·NCT00621452·12 enrolled

Acute Lymphoblastic Leukemia2 trials

Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation

Completed·FFred Hutchinson Cancer Center·Phase 1/2·NCT00052520·37 enrolled

Cellular Adoptive Immunotherapy in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndromes That Relapsed After Donor Stem Cell Transplant

Completed·FFred Hutchinson Cancer Center·Phase 1·NCT00107354

Patients With Advanced Solid Tumors1 trial

Interleukin-12 Plus Interleukin-2 in Treating Patients With Advanced Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00005604·25 enrolled

Myelodysplastic Syndrome1 trial

Interleukin-2 in Treating Patients With Myelodysplastic Syndrome

Completed·UUniversity of Washington·Phase 1·NCT00002746·24 enrolled

Advanced Cancer1 trial

Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer

Terminated·JJonsson Comprehensive Cancer Center·Phase 1·NCT03240861·5 enrolled

Intestinal Cancer1 trial

A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering

Completed·IIntima Bioscience, Inc.·Phase 1/2·NCT04426669·23 enrolled

Infusion1 trial

Long Term Continuous Infusion ch14.18/CHO Plus s.c. Aldesleukin (IL-2)

Unknown status·SSt. Anna Kinderkrebsforschung·Phase 1/2·NCT01701479·288 enrolled

High-Grade Squamous Intraepithelial Lesions1 trial

Immunotherapy With E6 T Cell Receptor (TCR) T Cells for Vulvar High-Grade Squamous Intraepithelial Lesions

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT03197025·1 enrolled

TED1 trial

Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT03745326·5 enrolled

Locally Advanced1 trial

Gene-Modified T Cells, Vaccine Therapy, and Ipilimumab in Treating Patients With Locally Advanced or Metastatic Malignancies

Terminated·JJonsson Comprehensive Cancer Center·Phase 1·NCT02070406·4 enrolled

Fallopian Tube Cancer1 trial

Genetically Modified T Cells and Decitabine in Treating Patients With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Active, not recruiting·RRoswell Park Cancer Institute·Phase 1·NCT03017131·9 enrolled

Advanced Malignancies1 trial

Gene and Vaccine Therapy in Treating Patients With Advanced Malignancies

Active, not recruiting·JJonsson Comprehensive Cancer Center·Phase 2·NCT01697527·6 enrolled

Ocular Melanoma1 trial

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT01814046·24 enrolled

Skin Lesions1 trial

Pre-Treatment of Highly Suspicious Pigmented Skin Lesions With Interleukin-2

Terminated·CCarman Giacomantonio·Phase 3·NCT03233828·1 enrolled

Autoimmunity1 trial

Interleukin-2 Therapy of Autoimmunity in Diabetes (ITAD)

Active, not recruiting·UUniversity of Oxford·Phase 2·NCT03782636·41 enrolled

Pembrolizumab1 trial

Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating Patients With Unresectable or Metastatic Transitional Cell Cancer Who Have Failed Cisplatin-Based Chemotherapy

Withdrawn·RRoswell Park Cancer Institute·Phase 2·NCT03935347

Recurrent Sarcoma1 trial

Modified T Cells, Chemotherapy, and Aldesleukin With or Without LV305 and CMB305 in Treating Participants With Advanced or Recurrent Sarcoma

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT03450122·15 enrolled

Hematological Malignancies1 trial

Donor Cord Blood T-Cell Infusion After Stem Cell Transplant in Treating Patients With Relapsed Hematological Malignancies

Terminated·MM.D. Anderson Cancer Center·Phase 1·NCT01630564·2 enrolled

Soft Tissue Sarcoma1 trial

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT03449108·30 enrolled

Chronic Lymphocytic Leukemia1 trial

Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia

Terminated·MMasonic Cancer Center, University of Minnesota·Phase 1/2·NCT00625729·6 enrolled

Glioblastoma Multiforme1 trial

Cellular Adoptive Immunotherapy in Treating Patients With Glioblastoma Multiforme

Completed·HHoag Memorial Hospital Presbyterian·Phase 2·NCT00331526·83 enrolled

Brain Tumors1 trial

Cytotoxic T Cells and Interleukin-2 in Treating Adult Patients With Recurrent Brain Tumors

Completed·UUniversity of Colorado, Denver·Phase 1·NCT00002572·10 enrolled

Metastatic1 trial

Phase II Study of Allo LMI Vaccine With IL-2 for Stable Metastatic Breast Ca

Terminated·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00784524·14 enrolled

Precursor B-Cell Acute Lymphoblastic Leukemia1 trial

Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma

Completed·SSt. Jude Children's Research Hospital·Phase 2·NCT01700946·80 enrolled

Acute Leukemia1 trial

Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Acute Leukemia

Completed·HHerbert Irving Comprehensive Cancer Center·Phase 2·NCT00008190

Metastatic Colorectal Cancer1 trial

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT00019591

Locally Advanced Solid Tumor1 trial

Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1

Completed·JJonsson Comprehensive Cancer Center·Phase 1·NCT02775292·1 enrolled

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00020462

Metastatic Solid Tumors1 trial

Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00019331

Glioma1 trial

Biological Therapy in Treating Patients With Primary or Advanced Glioma

Suspended·WWeill Medical College of Cornell University·Phase 2·NCT00003067

Chronic Myelogenous Leukemia1 trial

Chemotherapy Followed by Peripheral Stem Cell Transplantation And Biological Therapy in Treating Patients With Chronic Myelogenous Leukemia

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00005948

Hepatitis C1 trial

Interleukin-2 (IL-2), Pegylated Interferon (PEG-IFN Alfa-2b), and Ribavirin (RBV) Treatment in Patients With Hepatitis C and HIV Coinfection

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00015652·24 enrolled

Unresectable Cancer1 trial

Inhaled Interleukin-2 in Treating Patients With Metastatic or Unresectable Cancer

Terminated·UUniversity of Southern California·Phase 1·NCT00003009·16 enrolled

Head and Neck Cancer1 trial

Microsphere-Delivered Cytokines in Increasing Tumor Response in Lymphocytes From Patients With Head and Neck Cancer

Completed·NNYU Langone Health·N/A·NCT00899821

Myeloid Leukemia1 trial

Therapeutic Allogeneic Lymphocytes and Aldesleukin in Treating Patients With High-Risk or Recurrent Myeloid Leukemia After Undergoing Donor Stem Cell Transplant

Terminated·FFred Hutchinson Cancer Center·Phase 1/2·NCT00052598·7 enrolled

Treatment1 trial

CISH Inactivated TILs in the Treatment of NSCLC

Withdrawn·IIntima Bioscience, Inc.·Phase 1/2·NCT05566223

Leukemia1 trial

Chemotherapy Followed by Donor White Blood Cells Plus Interleukin-2 in Treating Patients With Acute Myeloid or Lymphocytic Leukemia

Completed·FFred Hutchinson Cancer Center·Phase 1/2·NCT00005802

Cytomegalovirus (CMV)1 trial

A Phase I Study of the Safety of Proleukin (Aldesleukin) in Combination With Ganciclovir and Antiretroviral Therapy in HIV Seropositive Patients With Cytomegalovirus (CMV) Retinitis

Completed·CChiron Corporation·Phase 1·NCT00002321

Malignant Glioma1 trial

CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT01454596·18 enrolled

Solid Tumors1 trial

Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors

Terminated·AAlaunos Therapeutics·Phase 1/2·NCT05194735·8 enrolled

Renal Cancer1 trial

Pilot Study of Denileukin Diftitox Plus High-Dose IL-2 for Patients With Metastatic Renal Cancer

Completed·NNorthwestern University·Phase 1·NCT00278369·20 enrolled

Colorectal Cancer1 trial

STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma

Withdrawn·—·Phase 1·NCT06626256

Radiation Therapy1 trial

Surgery and Radiation Therapy With or Without Interleukin-2 in Treating Patients With Cancer of the Mouth or Oropharynx

Unknown status·EEuropean Institute of Oncology·Phase 3·NCT00002702·260 enrolled

Gene Therapy1 trial

Non-Viral TCR Gene Therapy

Withdrawn·NNational Cancer Institute (NCI)·Phase 2·NCT04102436

Renal Cell Carcinoma1 trial

Aldesleukin in Participants With Metastatic Renal Cell Carcinoma or Metastatic Melanoma

Completed· Novartis logo

Novartis·Phase 4·NCT00414765·26 enrolled

COVID-191 trial

Survival TRial Using CytoKines in COVID-19 (STRUCK Trial)

Completed·UUniversity of Sao Paulo·Phase 3·NCT04724629·60 enrolled

HIV infection1 trial

A Phase II Study of Intermittent Recombinant Human Interleukin-2 (rhIL-2) by Intravenous or Subcutaneous Administration in Subjects With HIV Infection on Highly Active Antiretroviral Therapy (HAART) Compared to HAART Alone

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000870·200 enrolled

Lymphadenopathy1 trial

Phase I Trial of the Combination of Zidovudine and Recombinant Interleukin-2 in Patients With Persistent Generalized Lymphadenopathy

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000728·20 enrolled

Thyroid Cancer1 trial

Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing Human Thyroglobulin to People With Thyroglobulin Expressing Thyroid Cancer

Withdrawn·NNational Cancer Institute (NCI)·Phase 1/2·NCT02390739

Clear Cell Carcinoma1 trial

Bevacizumab and Aldesleukin in Treating Patients With Metastatic Clear Cell Carcinoma of the Kidney

Completed·—·Phase 2·NCT00853021·26 enrolled

Renal Transplantation1 trial

Ultra-low Dose Subcutaneous IL-2 in Renal Transplantation

Terminated·—·Phase 1/2·NCT02417870·2 enrolled

Unspecified1 trial

Anti-NY ESO-1 mTCR Peripheral Blood Lymphocytes

Terminated·—·Phase 1·NCT02774291·3 enrolled

Regulatory

FDA Approval Timeline[4]

May 5, 1992

PROLEUKIN

NDA BLA103293

May 5, 1992

PROLEUKIN

BLA BLA103293

Jan 9, 1998

PROLEUKIN

NDA BLA103293

Jan 9, 1998

PROLEUKIN

NDA BLA103293

Jun 27, 2000

PROLEUKIN

NDA BLA103293

Apr 8, 2009

PROLEUKIN

NDA BLA103293

Mar 17, 2010

PROLEUKIN

NDA BLA103293

Jul 6, 2010

PROLEUKIN

NDA BLA103293

Jul 19, 2011

PROLEUKIN

NDA BLA103293

Dec 16, 2011

PROLEUKIN

NDA BLA103293

Jul 30, 2012

PROLEUKIN

NDA BLA103293

May 6, 2015

PROLEUKIN

NDA BLA103293

May 17, 2019

PROLEUKIN

NDA BLA103293

Sep 29, 2023

PROLEUKIN

NDA BLA103293

Sources

References

[1]
ClinicalTrials.gov — 322 trial records for Aldesleukin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Aldesleukin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Aldesleukin. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA BLA103293). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Iovance Biotherapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Interleukin-2 Receptor Agonist[2]
Modality: Protein / enzyme[2]
Highest Phase: Phase 3[1]
Company: IIovance Biotherapeutics, Inc.

Proleukin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q3 2027

Q4 2027

Q1 2028

Trials by Indication[1]

Metastatic Melanoma32 trials

Melanoma16 trials

Kidney Cancer11 trials

Metastatic Cancer9 trials

Breast Cancer8 trials

Lymphoma8 trials

Neuroblastoma7 trials

Interleukin6 trials

Acute Myeloid Leukemia6 trials

Multiple Myeloma4 trials

Ovarian Cancer3 trials

Non-Small Cell Lung Cancer3 trials

Immunotherapy3 trials

Bone Marrow Transplantation3 trials

Type 1 Diabetes3 trials

Mycosis Fungoides2 trials

Papilloma2 trials

Effectiveness2 trials

Hematologic Cancer2 trials

HIV2 trials

Biological Therapy2 trials

Natural Killer Cell2 trials

Drug Therapy2 trials

Stem Cell Transplant2 trials

Prostate Cancer2 trials

Cancer2 trials

Mantle Cell Lymphoma2 trials

Acute Lymphoblastic Leukemia2 trials

Patients With Advanced Solid Tumors1 trial

Myelodysplastic Syndrome1 trial

Advanced Cancer1 trial

Intestinal Cancer1 trial

Infusion1 trial

High-Grade Squamous Intraepithelial Lesions1 trial

TED1 trial

Locally Advanced1 trial

Fallopian Tube Cancer1 trial

Advanced Malignancies1 trial

Ocular Melanoma1 trial

Skin Lesions1 trial

Autoimmunity1 trial

Pembrolizumab1 trial

Recurrent Sarcoma1 trial

Hematological Malignancies1 trial

Soft Tissue Sarcoma1 trial

Chronic Lymphocytic Leukemia1 trial

Glioblastoma Multiforme1 trial

Brain Tumors1 trial

Metastatic1 trial

Precursor B-Cell Acute Lymphoblastic Leukemia1 trial

Acute Leukemia1 trial

Metastatic Colorectal Cancer1 trial

Locally Advanced Solid Tumor1 trial

HIV-1 infection1 trial

Primary Peritoneal Cancer1 trial

Follicular Lymphoma1 trial

Metastatic Solid Tumors1 trial

Glioma1 trial

Chronic Myelogenous Leukemia1 trial

Hepatitis C1 trial

Unresectable Cancer1 trial

Head and Neck Cancer1 trial

Myeloid Leukemia1 trial

Treatment1 trial

Leukemia1 trial

Cytomegalovirus (CMV)1 trial

Malignant Glioma1 trial

Solid Tumors1 trial

Renal Cancer1 trial

Colorectal Cancer1 trial

Radiation Therapy1 trial